Trending:
-
21 May 2018
Opportunity abounds for pharma in binge eating disorder marketplace
Since being officially recognized as a distinct eating disorder by DSM-5 in 2013, binge eating disorder (BED) has quickly become a drug market ripe with opportunity due to a growing...
-
11 May 2018
AstraZeneca continues to invest in stem cell research
AstraZeneca (AZ) will bring funds and other substantial capabilities to the table in a collaboration on cardiovascular stem cell research.
-
10 May 2018
CPHI experts: 90% of current pipeline APIs are poorly soluble
Advances in solubility and surface area are being driven by a massive change in the solubility of pipeline APIs, claimed industry experts at the Solubility Enhancement and Improving Oral Bioavailability...
-
8 May 2018
New fund will address misuse of drugs in UK care homes
The UK National Health Service recently announced a £20m investment to fund 180 pharmacists and 60 pharmacy technicians to work in care homes.
-
4 May 2018
Gilead’s HCV portfolio disappoints amid pressure from AbbVie’s Mavyret
On 2 May, Gilead Sciences announced its Q1 2018 earnings, with the company’s hepatitis C virus (HCV) portfolio amassing just over $1bn in first quarter sales—slightly below a consensus forecast...
-
4 May 2018
The world’s first CAR-T therapy has been approved for a second indication
Kymriah (tisagenlecleucel) made history in August 2017 when it became the world’s first approved chimeric antigen receptor (CAR) T-cell therapy, and was indicated for pediatric and young adult patients with...
-
2 May 2018
Positive CHMP opinion on Prolia label expansion will further boost sales
The latest label expansion will boost Prolia sales even further by targeting a new patient population with high unmet needs.
-
25 April 2018
World Malaria Day 2018: to achieve eradication, malaria transmission must be stopped
On 25 April, the World Health Organization (WHO) member states celebrate World Malaria Day. This year’s theme, ‘Ready to Beat Malaria’, highlights the collective goal of the global malaria community...
-
25 April 2018
The late-stage type 2 diabetes pipeline is dominated by ‘me-too’ drugs
Type 2 diabetes (T2D) is a chronic disease characterised by insulin resistance and pancreatic β-cell failure, with an underlying genetic predisposition that is heavily influenced by diet and lifestyle.
-
24 April 2018
Tremfya approval: increasing options for psoriasis treatment
Johnson & Johnson’s (J&J) Tremfya (guselkumab) has recently been granted approval for the treatment of adults suffering from moderate-to-severe plaque psoriasis in Australia, Brazil, and Japan. J&J has licensed Tremfya...
